EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical exome sequencing data from patients with inborn errors of immunity: Cohort level diagnostic yield and the benefit of systematic reanalysis

Emil E Vorsteveld, Caspar I Van der Made, Sanne P Smeekens, Janneke H Schuurs-Hoeijmakers, Galuh Astuti, Heleen Diepstra, Christian Gilissen, Evelien Hoenselaar, Alice Janssen, Kees van Roozendaal, Jettie Sikkema-van Engelen, Wouter Steyaert und 30 weitere

Clinical Immunology · 2024-11 · 268 · 110375

DOI: 10.1016/j.clim.2024.110375 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Immunology, 2024-11. Verfasst von Emil E Vorsteveld und 41 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands; RadboudUMC Research Institute for Medical Innovation, Rad…. Hauptthemen laut MEDLINE: Exome Sequencing, Exome. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 108 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Research Council, Horizon 2020, Dutch Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

While next generation sequencing has expanded the scientific understanding of Inborn Errors of Immunity (IEI), the clinical use and re-use of exome sequencing is still emerging. We revisited clinical exome data from 1300 IEI patients using an updated in silico IEI gene panel. Variants were classified and curated through expert review. The molecular diagnostic yield after standard exome analysis was 11.8 %. Through systematic reanalysis, we identified variants of interest in 5.2 % of undiagnosed patients, with 76.7 % being (candidate) disease-causing, providing a (candidate) diagnosis in 15.2 % of our cohort. We find a 1.7 percentage point increase in conclusive molecular diagnoses. We find a high degree of actionability in patients with a genetic diagnosis (76.4 %). Despite the modest absolute diagnostic gain, these data support the benefit of iterative exome reanalysis in IEI patients, conveying the notion that our current understanding of genes and variants involved in IEI is by far not saturated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Exome SequencingExomeHumansHigh-Throughput Nucleotide SequencingCohort StudiesMaleImmune System DiseasesFemale

Stichwörter der Autor:innen

Autoimmune disordersAutoinflammatory disordersClinical exome sequencingExome reanalysisGenomicsInborn errors of immunityLongitudinal follow-upNGS-based sequencingPrimary immunodeficiencies

Autor:innen und Institutionen

  • Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands; RadboudUMC Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands; RadboudUMC Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands; Department…
  • Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Department of Clinical Genetics, Maastricht University Medical Center+, Maastricht, The Netherlands.
  • Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands; Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands; Laboratory of Cancer Genetics and Tumor Biology, Translational Medicine Research Unit and Biocenter Oulu, University of Oulu, O…

Förderung

  • European Research Council
  • Horizon 2020
  • Dutch Research Council

Zitieren

APA

Vorsteveld, E. E., Van der Made, C. I., Smeekens, S. P., Schuurs-Hoeijmakers, J. H., Astuti, G., Diepstra, H., Gilissen, C., Hoenselaar, E., Janssen, A., van Roozendaal, K., Engelen, J. S., Steyaert, W., Weiss, M. M., Yntema, H. G., Mantere, T., AlZahrani, M. S., van Aerde, K., Derfalvi, B., Faqeih, E. A., …, & Hoischen, A. (2024). Clinical exome sequencing data from patients with inborn errors of immunity: Cohort level diagnostic yield and the benefit of systematic reanalysis. Clinical Immunology, 268, 110375. https://doi.org/10.1016/j.clim.2024.110375

Vancouver

Vorsteveld EE, Van der Made CI, Smeekens SP, Schuurs-Hoeijmakers JH, Astuti G, Diepstra H, et al. Clinical exome sequencing data from patients with inborn errors of immunity: Cohort level diagnostic yield and the benefit of systematic reanalysis. Clinical Immunology. 2024;268:110375. doi:10.1016/j.clim.2024.110375

BibTeX
@article{Vorsteveld2024,
  author = {Vorsteveld, Emil E and Van der Made, Caspar I and Smeekens, Sanne P and Schuurs-Hoeijmakers, Janneke H and Astuti, Galuh and Diepstra, Heleen and Gilissen, Christian and Hoenselaar, Evelien and Janssen, Alice and van Roozendaal, Kees and Engelen, Jettie Sikkema-van and Steyaert, Wouter and Weiss, Marjan M and Yntema, Helger G and Mantere, Tuomo and AlZahrani, Mofareh S and van Aerde, Koen and Derfalvi, Beata and Faqeih, Eissa Ali and Henriet, Stefanie S V and van Hoof, Elise and Idressi, Eman and Issekutz, Thomas B and Jongmans, Marjolijn C J and Keski-Filppula, Riikka and Krapels, Ingrid and Te Loo, Maroeska and Mulders-Manders, Catharina M and Ten Oever, Jaap and Potjewijd, Judith and Sarhan, Nora Tarig and Slot, Marjan C and Terhal, Paulien A and Thijs, Herman and Vandersteen, Anthony and Vanhoutte, Els K and van de Veerdonk, Frank and van Well, Gijs and Netea, Mihai G and all members of the Radboud University Medical Center multidisciplinary immune-disease board, all members of the Radboud University Medical Center multidisciplinary immune-disease board and Simons, Annet and Hoischen, Alexander},
  title = {Clinical exome sequencing data from patients with inborn errors of immunity: Cohort level diagnostic yield and the benefit of systematic reanalysis},
  journal = {Clinical Immunology},
  year = {2024},
  volume = {268},
  pages = {110375},
  doi = {10.1016/j.clim.2024.110375}
}
Kostenlos starten →